Matches in SemOpenAlex for { <https://semopenalex.org/work/W1891698889> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W1891698889 endingPage "1133" @default.
- W1891698889 startingPage "1122" @default.
- W1891698889 abstract "Phosphodiesterase type 5 (PDE5) inhibitors have become standard treatment for erectile dysfunction (ED).To prospectively evaluate the safety and efficacy of avanafil, a novel PDE5 inhibitor, in men with mild to severe ED.In this multicenter, double-blind, Phase 3 trial, 646 subjects were randomized to receive avanafil (50 mg, 100 mg, 200 mg) or placebo throughout a 12-week treatment period. Subjects were instructed to take study drug 30 minutes prior to initiation of sexual activity. At least a 12-hour separation time between doses was required; no restrictions were placed on food or alcohol intake.Improvement in erectile function (EF) was measured by Sexual Encounter Profile questions 2 and 3 (SEP2 and SEP3) and by the EF domain of the International Index of Erectile Function (IIEF) questionnaire.Mean change in percentage of successful sexual attempts (SEP2 and SEP3) and IIEF-EF domain score significantly favored all doses of avanafil over placebo (P ≤ 0.001). Secondary analyses demonstrated achievement of successful intercourse by subjects within 15 minutes of dosing. Of the 300 sexual attempts made during this interval, 64% to 71% were successful in avanafil-treated subjects compared with 27% in placebo-treated subjects. Successful intercourse was also demonstrated >6 hours post dosing, with 59% to 83% of the 80 sexual attempts successful in avanafil-treated subjects compared with 25% of placebo-treated subjects. The most commonly reported adverse events in subjects taking avanafil included headache, flushing, and nasal congestion; there were no drug-related serious adverse events.Following 12 weeks of avanafil treatment without food or alcohol restrictions, significant improvements in sexual function were observed with all 3 doses of avanafil compared with placebo. Successful intercourse was observed as early as 15 minutes and >6 hours after dosing in some subjects. Avanafil was generally well tolerated for the treatment of ED." @default.
- W1891698889 created "2016-06-24" @default.
- W1891698889 creator A5019984709 @default.
- W1891698889 creator A5025575327 @default.
- W1891698889 creator A5031972880 @default.
- W1891698889 creator A5036302146 @default.
- W1891698889 creator A5049442923 @default.
- W1891698889 creator A5050841036 @default.
- W1891698889 creator A5060265604 @default.
- W1891698889 creator A5079427154 @default.
- W1891698889 date "2012-04-01" @default.
- W1891698889 modified "2023-10-14" @default.
- W1891698889 title "A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Safety and Efficacy of Avanafil in Subjects with Erectile Dysfunction" @default.
- W1891698889 cites W1541912022 @default.
- W1891698889 cites W1989446771 @default.
- W1891698889 cites W2004405846 @default.
- W1891698889 cites W2040942287 @default.
- W1891698889 cites W2045073455 @default.
- W1891698889 cites W2068006406 @default.
- W1891698889 cites W2070601048 @default.
- W1891698889 cites W2085095071 @default.
- W1891698889 cites W2086240335 @default.
- W1891698889 cites W2108797351 @default.
- W1891698889 cites W2117617888 @default.
- W1891698889 cites W2131146176 @default.
- W1891698889 cites W2145192033 @default.
- W1891698889 cites W2297358297 @default.
- W1891698889 doi "https://doi.org/10.1111/j.1743-6109.2011.02629.x" @default.
- W1891698889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22248153" @default.
- W1891698889 hasPublicationYear "2012" @default.
- W1891698889 type Work @default.
- W1891698889 sameAs 1891698889 @default.
- W1891698889 citedByCount "83" @default.
- W1891698889 countsByYear W18916988892012 @default.
- W1891698889 countsByYear W18916988892013 @default.
- W1891698889 countsByYear W18916988892014 @default.
- W1891698889 countsByYear W18916988892015 @default.
- W1891698889 countsByYear W18916988892016 @default.
- W1891698889 countsByYear W18916988892017 @default.
- W1891698889 countsByYear W18916988892018 @default.
- W1891698889 countsByYear W18916988892019 @default.
- W1891698889 countsByYear W18916988892020 @default.
- W1891698889 countsByYear W18916988892021 @default.
- W1891698889 countsByYear W18916988892022 @default.
- W1891698889 countsByYear W18916988892023 @default.
- W1891698889 crossrefType "journal-article" @default.
- W1891698889 hasAuthorship W1891698889A5019984709 @default.
- W1891698889 hasAuthorship W1891698889A5025575327 @default.
- W1891698889 hasAuthorship W1891698889A5031972880 @default.
- W1891698889 hasAuthorship W1891698889A5036302146 @default.
- W1891698889 hasAuthorship W1891698889A5049442923 @default.
- W1891698889 hasAuthorship W1891698889A5050841036 @default.
- W1891698889 hasAuthorship W1891698889A5060265604 @default.
- W1891698889 hasAuthorship W1891698889A5079427154 @default.
- W1891698889 hasConcept C126322002 @default.
- W1891698889 hasConcept C126894567 @default.
- W1891698889 hasConcept C142724271 @default.
- W1891698889 hasConcept C168563851 @default.
- W1891698889 hasConcept C197934379 @default.
- W1891698889 hasConcept C204787440 @default.
- W1891698889 hasConcept C27081682 @default.
- W1891698889 hasConcept C2775871022 @default.
- W1891698889 hasConcept C2777288759 @default.
- W1891698889 hasConcept C2779929075 @default.
- W1891698889 hasConcept C71924100 @default.
- W1891698889 hasConceptScore W1891698889C126322002 @default.
- W1891698889 hasConceptScore W1891698889C126894567 @default.
- W1891698889 hasConceptScore W1891698889C142724271 @default.
- W1891698889 hasConceptScore W1891698889C168563851 @default.
- W1891698889 hasConceptScore W1891698889C197934379 @default.
- W1891698889 hasConceptScore W1891698889C204787440 @default.
- W1891698889 hasConceptScore W1891698889C27081682 @default.
- W1891698889 hasConceptScore W1891698889C2775871022 @default.
- W1891698889 hasConceptScore W1891698889C2777288759 @default.
- W1891698889 hasConceptScore W1891698889C2779929075 @default.
- W1891698889 hasConceptScore W1891698889C71924100 @default.
- W1891698889 hasIssue "4" @default.
- W1891698889 hasLocation W18916988891 @default.
- W1891698889 hasLocation W18916988892 @default.
- W1891698889 hasOpenAccess W1891698889 @default.
- W1891698889 hasPrimaryLocation W18916988891 @default.
- W1891698889 hasRelatedWork W1975699209 @default.
- W1891698889 hasRelatedWork W2002583647 @default.
- W1891698889 hasRelatedWork W2037909123 @default.
- W1891698889 hasRelatedWork W2050722366 @default.
- W1891698889 hasRelatedWork W2067444868 @default.
- W1891698889 hasRelatedWork W2087566648 @default.
- W1891698889 hasRelatedWork W2107187998 @default.
- W1891698889 hasRelatedWork W2170601172 @default.
- W1891698889 hasRelatedWork W282266550 @default.
- W1891698889 hasRelatedWork W4245421692 @default.
- W1891698889 hasVolume "9" @default.
- W1891698889 isParatext "false" @default.
- W1891698889 isRetracted "false" @default.
- W1891698889 magId "1891698889" @default.
- W1891698889 workType "article" @default.